{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:39:44Z","timestamp":1793104784297,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["RD24\/0004\/0014"],"award-info":[{"award-number":["RD24\/0004\/0014"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PI24\/01711"],"award-info":[{"award-number":["PI24\/01711"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.nefroe.2026.501464","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:17:26Z","timestamp":1775647046000},"page":"501464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complement blockade: Therapeutic promises and remaining challenges in clinical practice"],"prefix":"10.1016","volume":"46","author":[{"given":"Gema","family":"Fern\u00e1ndez-Ju\u00e1rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Azores-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Le\u00f3n-Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"V\u00e1zquez-Raso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Soriano-Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Rivas Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Vega Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Shabaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2026.501464_bib0005","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2026.501464_bib0010","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2026.501464_bib0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2026.501464_bib0020","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501464_bib0025","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ekir.2022.02.021","article-title":"The rational use of complement inhibitors in kidney diseases","volume":"7","author":"Fakhouri","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2026.501464_bib0030","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2026.501464_bib0035","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1182\/bloodadvances.2022006960","article-title":"Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study","volume":"6","author":"Jang","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.nefroe.2026.501464_bib0040","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2026.501464_bib0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ekir.2024.09.030","article-title":"Efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent complement 3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis","volume":"10","author":"Bomback","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2026.501464_bib0050","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1681\/ASN.0000000526","article-title":"Safety and efficacy of avacopan in patients with complement 3 glomerulopathy: randomized, double-blind clinical trial","volume":"36","author":"Bomback","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501464_bib0055","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3390\/cells12050712","article-title":"Diagnostic and prognostic comparison of immune-complex-mediated membranoproliferative glomerulonephritis and C3 glomerulopathy","volume":"12","author":"Kovala","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.nefroe.2026.501464_bib0060","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.kint.2020.05.053","article-title":"Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties","volume":"98","author":"Fakhouri","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501464_bib0065","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2026.501464_bib0070","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nefroe.2026.501464_bib0075","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2026.501464_bib0080","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial","volume":"36","author":"Lafayette","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501464_bib0085","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00428-020-02800-0","article-title":"Complement activation is associated with crescent formation in IgA nephropathy","volume":"477","author":"Itami","year":"2020","journal-title":"Virchows Arch"},{"key":"10.1016\/j.nefroe.2026.501464_bib0090","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1681\/ASN.2011121186","article-title":"Pathology after eculizumab in dense deposit disease and C3 GN","volume":"23","author":"Herlitz","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501464_bib0095","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2026.501464_bib0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.kint.2023.10.013","article-title":"Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","author":"Lucientes-Continente","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501464_bib0105","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.kint.2024.07.020","article-title":"Inhibition of complement factor C5a or C5aR for cholesterol crystal embolism-related vascular thrombosis with microvascular injury and its consequences","volume":"106","author":"Zhao","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501464_bib0110","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.kint.2020.09.033","article-title":"Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis","volume":"99","author":"Boudhabhay","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501464_bib0115","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1177\/09612033221106301","article-title":"Kidney thrombotic microangiopathy in lupus nephritis: impact on treatment and prognosis","volume":"31","author":"Massicotte-Azarniouch","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2026.501464_bib0120","article-title":"Evidences of histologic thrombotic microangiopathy and the impact in renal outcomes of patients with IgA nephropathy","volume":"15","author":"Neves PDM de","year":"2020","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"10.1016\/j.nefroe.2026.501464_bib0125","doi-asserted-by":"crossref","first-page":"ii28","DOI":"10.1093\/ckj\/sfad198","article-title":"Targeting complement in IgA nephropathy","volume":"16","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2026.501464_bib0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.kint.2023.09.001","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501464_bib0135","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.kint.2018.09.027","article-title":"Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis","volume":"95","author":"Wilson","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501464_bib0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40291-022-00620-3","article-title":"Exploratory prognostic biomarkers of complement-mediated thrombotic microangiopathy (CM-TMA) in adults with atypical hemolytic uremic syndrome (aHUS): analysis of a phase III study of ravulizumab","volume":"27","author":"Cammett","year":"2023","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.nefroe.2026.501464_bib0145","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s10067-020-05499-1","article-title":"Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis","volume":"40","author":"Mejia-Vilet","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nefroe.2026.501464_bib0150","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2215\/CJN.02790313","article-title":"Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN","volume":"8","author":"Gou","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501464_bib0155","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.nefroe.2026.501464_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100079","article-title":"The complement system: biology, pathology, and therapeutic interventions","volume":"77","author":"Li","year":"2025","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.nefroe.2026.501464_bib0165","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2215\/CJN.15241219","article-title":"Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease","volume":"15","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501464_bib0170","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrneph.2010.85","article-title":"C3 glomerulopathy: a new classification","volume":"6","author":"Fakhouri","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefroe.2026.501464_bib0175","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2026.501464_bib0180","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501464_bib0185","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2026.501464_bib0190","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.kint.2017.03.041","article-title":"Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy","volume":"92","author":"Tortajada","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501464_bib0195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2025.01.014","article-title":"Mass spectrometry with data-independent acquisition for the identification of target antigens in membranous nephropathy","volume":"86","author":"Morelle","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2026.501464_bib0200","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2249.1997.4261438.x","article-title":"Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice","volume":"110","author":"Sheerin","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nefroe.2026.501464_bib0205","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/j.1600-6143.2006.01356.x","article-title":"C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings","volume":"6","author":"Haas","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2026.501464_bib0210","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2012.313","article-title":"Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"83","author":"Gou","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2026.501464_bib0215","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1007\/s10067-016-3384-9","article-title":"Circulating C3 levels predict renal and global outcome in patients with renal vasculitis","volume":"35","author":"Villacorta","year":"2016","journal-title":"Clin Rheumatol"}],"updated-by":[{"DOI":"10.1016\/j.nefroe.2026.501561","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251426000842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251426000842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:37:38Z","timestamp":1776267458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251426000842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2013251426000842"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2026.501464","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement blockade: Therapeutic promises and remaining challenges in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2026.501464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2025.501464","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501464"}}